MG
REGN icon

Mather Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Mather Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$493K Buy
791
+210
+36% +$143K ﹤0.01% 537
2026
Q1 		$449K Sell
581
-133
-19% -$102K ﹤0.01% 521
2025
Q4 		$551K Buy
714
+272
+62% +$185K 0.01% 387
2025
Q3 		$249K Buy
+442
New +$250K ﹤0.01% 571
2025
Q2 		– Sell
-1,090
Closed -$691K – 1463
2025
Q1 		$691K Buy
1,090
+183
+20% +$126K 0.01% 314
2024
Q4 		$646K Sell
907
-65
-7% -$54.5K 0.01% 300
2024
Q3 		$1.02M Sell
972
-172
-15% -$191K 0.01% 242
2024
Q2 		$1.1M Buy
1,144
+95
+9% +$92.1K 0.01% 253
2024
Q1 		$921K Buy
1,049
+4
+0.4% +$3.8K 0.01% 235
2023
Q4 		$918K Sell
1,045
-14
-1% -$11.5K 0.01% 242
2023
Q3 		$872K Buy
1,059
+127
+14% +$99.8K 0.02% 237
2023
Q2 		$669K Buy
932
+560
+151% +$432K 0.01% 295
2023
Q1 		$305K Buy
372
+38
+11% +$28.7K 0.01% 393
2022
Q4 		$241K Buy
334
+11
+3% +$8.12K ﹤0.01% 432
2022
Q3 		$222K Buy
+323
New +$203K ﹤0.01% 433
2021
Q4 		– Sell
-477
Closed -$289K – 396
2021
Q3 		$289K Buy
+477
New +$296K 0.01% 228

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Mather Group's REGN Position: Q2 2026 in Review

Mather Group increased its Regeneron Pharmaceuticals (REGN) stake by 36% in Q2 2026, buying an estimated $143K and bringing the position to 791 shares worth $493K. The position accounts for ﹤0.01% of the portfolio, ranked #537.

Mather Group first reported a position in REGN in Q3 2021 and has held it in 16 quarters since. The position peaked at $1.1M in Q2 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Mather Group held 791 shares of Regeneron Pharmaceuticals worth $493K as of Q2 2026.
  • Mather Group bought 210 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $143K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #537 holding.
  • Mather Group first reported a position in Regeneron Pharmaceuticals in Q3 2021 and has held it in 16 quarters since.
  • Mather Group's Regeneron Pharmaceuticals position peaked at $1.1M in Q2 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.